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DOI: http://dx.doi.org/10.1016/j.hemonc.2015.06.008OBJECTIVE/BACKGROUND: There are reports about the presence of paroxysmal nocturnal hemoglobinuria
(PNH) clones in multiple myeloma (MM), but these have been demonstrated only in red blood cells (RBCs)
and the previous reports utilized an obsolete diagnostic method. We carried out a study to identify the clones
by flow cytometry (FC) and to understand their clinical significance.
METHODS: A prospective study on consecutive patients with newly diagnosed MM who were candidates for
autologous stem cell transplantation (ASCT) from 2008 to 2012. We screened peripheral blood samples by FC
for CD55- and/or CD59-deficient RBC, neutrophils, and monocytes. PNH testing was carried out at diagnosis,
before ASCT and 3 months after ASCT, as well as sporadically during MM remission and at disease relapse.
RESULTS: A total of 31 patients were included in the study. PNH clones reaching a median size of 10.8% (range
4.0–18.7%) were found in 10 patients (32.3%). Clones were detected at diagnosis in nine patients and 3 months
after ASCT in one patient. A correlation between the presence of the clones and subclinical hemolysis was
observed. Nevertheless, the presence of the clones did not influence the overall management and prognosis
of the patients.
CONCLUSION: We confirmed findings of previous reports with current diagnostic guidelines and showed that
although the size of the clones may be relatively large, their presence is probably not detrimental. The clinical
significance of these clones and the possible mechanisms underlying their expansion in MM must be a subject of
further investigation.
KEYWORDS: Autologous stem cell transplantation; Multiple myeloma; Paroxysmal nocturnal hemoglobinuria; PIG-A geneParoxysmal nocturnal hemoglobinuria (PNH)is an acquired stem cell clonal disorder.Pathogenesis involves mutation of the PIG-A
gene leading to defective synthesis of the glycosylphos-
phatidylinositol (GPI) bridge, which is essential for
binding several surface proteins on the membrane ofcells.1,2 The biology behind mutant clone expansion
has not yet been elucidated, but existing theories have
suggested immunological or other mechanisms.3–6
Missing surface proteins include decay-accelerating
factor (CD55) and membrane inhibitor of reactive
lysis (CD59) that protect red blood cells (RBCs) fromarter 2015
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lysis by activated complement, leading to intravascular
hemolysis.7,8 The classic triad of PNH symptoms
includes hemolysis, bone marrow insufﬁciency, and
venous thromboses.9
There is evidence that very small PNH clones
may be present in healthy individuals.10 The presence
of clones in association with myelodysplastic
syndromes (MDSs) and aplastic anemia (AA) has
also been described.11,12 There have also been reports
regarding the presence of clones in patients with
lymphoproliferative disorders and plasma cell
dyscrasias.13–15 These observations were based on
obsolete technology for clone detection.16,17;
however, a recent work published after we
commenced our study identiﬁed CD55 RBC by ﬂow
cytometry (FC) in multiple myeloma (MM)
patients.18
We investigated the presence of PNH clones by
FC in MM and aimed to elucidate their possible clin-
ical signiﬁcance in relation to autologous stem cell
transplantation (ASCT).MATERIALS AND METHODS
Patients
This prospective study was conducted from 2008 to
2012 in Metaxa Hospital (Piraeus, Greece) in collab-
oration with the Department of Haematology, Athens
University Medical School (Athens, Greece). The
study included consecutive patients with a newly diag-
nosed MM who were candidates for ASCT. Thirty-
one patients (19 men and 12 women) were included.
The study was approved by the Institutional Review
Board.
Detection of PNH-type cells by FC: Timing of
clone detection
FC testing for PNH was performed in all MM
patients entering the study at the time of diagnosis.
Further tests were performed only on patients sub-
jected to ASCT, prior to the procedure (after induc-
tion chemotherapy) and 3 months after ASCT. For
patients treated with a tandem ASCT, PNH testing
was also conducted 3 months after the second proce-
dure. Samples were also tested at intervals of 6–
12 months during follow-up and/or at relapse.
Sample preparation
For analysis of GPI-linked antigens on white blood
cells (WBCs), 100 lL of fresh blood was added to
each tube containing mixtures of ﬂuorochrome-
labeled monoclonal antibodies (mAbs) according to
the manufacturer’s recommendations. Samples wereHematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015then incubated at 4 C in the dark for 20 min, follow-
ing which 1 mL of VersaLyse lysing solution
(Beckman Coulter, Brea, CA, USA) was added to
each tube and the tubes were incubated again for
another 10 min at room temperature. The tubes were
then centrifuged for 5 min at 300g, washed two times
with 1% sodium azide in 2 mL phosphate-buffered
saline (PBS), resuspended in 1% paraformaldehyde
in 2 mL PBS and stored at 4 C in the dark for no
longer than 1 day until further analysis.
For analysis of GPI-linked antigens on RBCs,
10 lL of whole blood was diluted into 2 mL of
PBS; 100 lL of this diluted solution was then added
to each tube containing mixtures of ﬂuorochrome-
labeled mAbs for RBC. he cells were handled as for
WBC, but without the addition of the RBC lysis
solution.Flow cytometry
PNH-type granulocytes were detected using a combi-
nation of CD15, CD45, CD55, and CD59. CD15
and CD45 were used to indentify granulocytes.
Antibodies to CD15 phycoerythrin (PE; clone
80H5), CD45 PE–cyanine 5 tandem (PC5; clone
J.33), and CD59 ﬂuorescein isothiocyanate (FITC;
clone P282E) from Beckman Coulter and CD55-
FITC (clone IA10) from BD Biosciences (Franklin
Lakes, NJ, USA) were used.
For the detection of PNH-type monocytes, a com-
bination of CD14, CD45, CD55, and CD59 was
used. CD14 and CD45 were used to identify mono-
cytes. Antibody to CD14 PE (clone M5E2) from
BD Biosciences was used.
PNH-type RBCs were detected using a combina-
tion of antiglycophorin A, CD55, and CD59.
Antibodies to CD55 PE (clone IA10) and CD59
PE [clone p282(H19)] from BD Biosciences and
antiglycophorin A FITC (clone 11E4B-7-6) from
Beckman Coulter were used.Flow cytometric analysis
Flow cytometric analysis was performed using an
FC500 ﬂow cytometer (Beckman Coulter). For each
sample, at least 100,000 CD15+ granulocytes or
1,000,000 glycophorin A+ RBCs within the corre-
sponding gate were analyzed.Analysis
The appropriate gating strategy was implemented
depending on the population evaluated. Granulo
cytes and monocytes were distinguished using forward
and side scatter that encompassed each population151
152
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and were further identiﬁed using side scatter and
CD45. Then, each population was further deﬁned
using lineage-speciﬁc markers (CD15 for granulo-
cytes, CD14 for monocytes, and glycophorin A for
RBCs). The protocol followed for the identiﬁcation
of PNH-type cells is presented in Fig. 1.Figure 1. (A–F) Protocol for identification of PNH-type granulocytes and RB
(B) CD45 and side scatter gates used to better define granulocytes. (C) Exp
granulocytes (defined in B): Percentage of PNH-type granulocytes (CD15CD5
cell gate to define RBCs. (F) Expression of CD59 by glycophorin-A+ RBC
RBCs/total glycophorin-A+ RBCs) was 0.4%. Note: RBC = red blood cell; PData collection
Clinical and laboratory parameters were recorded at
the same intervals as mentioned earlier for FC analy-
sis. We also collected data on myeloma treatment
modalities, toxicities, and response. In addition, dura-
tion of response and time of death were noted.Cs. (A) Forward and side scatter gates used to distinguish granulocytes.
ression of CD15 by gated cells from B. (D) Expression of CD55 by CD15
5 granulocytes/total CD15 granulocytes) was 0.7%. (E) Glycophorin-A+
s (defined in E). Percentage of PNH-type RBCs (glycophorin-A+ D59
NH = paroxysmal nocturnal hemoglobinuria.
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The distribution of the clone among the disease char-
acteristics was evaluated using the chi-square test. The
inﬂuence of the clone in laboratory tests was analyzed
by independent samples t test.
Kaplan–Meier curves were used to illustrate the
overall survival (OS) and progression-free survival
(PFS) distribution curves. The log-rank statistic was
used to evaluate the OS and PFS distribution curves
between patients with and without clone at diagnosis.
All tests were two sided; the level of statistical signif-
icance was set at 5%.RESULTS
All patients were white. Mean age of the patients was
60.1 (47–72) years. Twenty-eight patients had a diag-
nosis of MM and three had a diagnosis of plasma cell
leukemia. An ASCT was offered to 24 patients; three
cases were considered noneligible for ASCT at the
time of the procedure due to comorbidities, two died
during or after induction chemotherapy, and two were
lost to follow-up before ASCT. Patient characteristics
are summarized in Table 1.
Median patient follow-up period was 35 months
(range 2–71). PNH testing included a median of
three samples for each patient (range 1–6) and a med-
ian interval of 14 months (range 0–40) between the
ﬁrst and last samples. Of these, a median of two sam-
ples (range 1–4) was tested after ASCT and the med-
ian time between ASCT and the last sample was
found to be 11 months (range 3–34).
Clones with a PNH phenotype were identiﬁed in
10 of the 31 patients (32.3%; 5 men and 5 women).
Nine patients had a diagnosis of MM and one of
plasma cell leukemia. The clones were present at diag-
nosis in nine patients and they appeared following
ASCT in one patient. Of the nine patients presenting
with PNH clones at diagnosis, seven underwent
ASCT, one was excluded following an ASCT team
decision, and one was lost to follow-up after induction
chemotherapy.
Six of 31 cases (19.4%) were deﬁcient in both
CD55 and CD59; three had an isolated CD59 deﬁ-
ciency (9.7%) and one had an isolated CD55 deﬁ-
ciency (3.2%). An interesting correlation between
female sex and deﬁciency of both CD55 and CD59
was noted (p = .048). The PNH phenotype was
observed in all myeloid cell lines (RBC, neutrophils,
monocytes) in eight patients. Two patients demon-
strated CD55 and/or CD59 deﬁciency in RBC and
neutrophils only. Table 2 presents the summary ofHematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015cases where PNH cells were identiﬁed, along with
clone characteristics.
The clones attained a mean size of up to 10.8%
(range 4.0–18.7%). This reﬂected the largest PNH
population in each patient in any of the measure-
ments. Clone sizes were decreasing as MM treatment
progressed. Of the seven patients with PNH cells at
diagnosis who were subjected to ASCT, clones disap-
peared after induction chemotherapy in two patients
(Patients 2 and 3) and 3 months after ASCT in
one patient (Patient 5). Two more patients showed
a progressive reduction in clone size and eventually
became negative 12 months after ASCT (Patients 4
and 7), whereas another patient (Patient 6) demon-
strated a decreasing clone size 12 months after
ASCT. Patient 1 showed refractory disease despite
tandem ASCT and demonstrated a ﬂuctuating clone
size, loosely correlating with MM activity. For the
two patients (Patients 8 and 10) who were not sub-
jected to ASCT, no additional samples were tested
for PNH after diagnosis. Finally, one patient, who
was negative for PNH cells at diagnosis, demonstrated
CD59 cells 3 months after ASCT (Patient 9). Clone
disappeared in subsequent testing, 12 months after
ASCT. Clone recurrence was not observed in any of
the patients, although four of them relapsed. The clone
size in relation to ASCT is depicted in Fig. 2.
No patient had clinical symptoms or signs attribu-
table to the clones. Nevertheless, we observed that
patients with clones had signiﬁcantly higher reticulo-
cyte counts (p = .029) and lactate dehydrogenase
(LDH) levels (p = .013) compared with those with-
out PNH clones. Hemoglobin level, however, did
not correlate with the presence of the clones.
Another ﬁnding is that patients with clones at diagno-
sis had signiﬁcantly less bone marrow plasmacytic
inﬁltration (p = .050). A trend was, ﬁnally, observed
between the presence of the clone and advanced
(Scale 3) bone disease (p = .080). No correlation
was observed between the presence of clones and
other parameters, including age, sex, speciﬁc diagno-
sis, M-protein type, and disease stage.
Response to induction chemotherapy and ASCT,
as well as hematological toxicity from either procedure
did not differ between patients with and without
clones. Stem cell harvest prior to ASCT and hemato-
logical recovery time following ASCT were similar in
both groups. The OS and PFS were not affected by
the presence of the clones either (Fig. 3). Clinical
and laboratory characteristics, and the comparisons
between patients with and without clones are summa-
rized in Table 1.153
Table 1. Patient characteristics and correlation of clinical and laboratory parameters with the presence of PNH Clones at diagnosis.
All patients at
diagnosis (n = 31)
Patients with PNH clones
at diagnosis (n = 9)
Patients without PNH clones
at diagnosis (n = 22)
p
Age (y) 47–72 (mean 60.1) 47–72 (mean 57.9) 47–63 (mean 61.0) .272
Sex .218
Male 19 4 15
Female 12 5 7
Diagnosis .862
Multiple myeloma 28 8 20
Plasma cell leukemia 3 1 2
Stage (ISS) .621
I 9 3 6
II 7 1 6
III 15 5 10
M-protein type .670
IgG-j 9 3 6
IgG-k 9 3 6
IgA-j 2 1 1
IgA-k 1 0 1
IgD-k 1 0 1
j-Light chains 4 1 3
k-Light chains 5 1 4
Mean laboratory values at diagnosis
Hb (g/dL) 10.7 10.8 9.0 .972
Reticulocytes (%) 1.47 2.42 1.22 .029
WBC (·109/L) 6.739 6.577 6810 .858
Platelets (·109/L) 211 222 206 .600
ESR (mm/h) 53.88 58.44 52.03 .703
Creatinine (mg/dL) 1.24 1.19 1.26 .807
Calcium (mg/dL) 9.90 9.77 9.94 .808
Albumin (g/dL) 3.80 4.20 3.68 .260
LDH (U/L) 187.9 225.89 171.57 .013
b2-microglobulin (lg/L) 5912 6763 5581 .572
Bone marrow infiltration (%) 46.88 28.56 58.5 .050
Bone Disease Scale 3 (No. of patients) 12 6 6 .080
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Table 2. Summary of cases where PNH cells were identified, along with clone characteristics.
Patient number Sexa CD55b CD59b Cell linesc Clone size (%)d Timinge
1 Male +  R, N, M 10 Diagnosis
2 Male +  R, N, M 4 Diagnosis
3 Female   R, N, M 12.8 Diagnosis
4 Female   R, N, M 12 Diagnosis
5 Male   R, N, M 11.1 Diagnosis
6 Male  + R, N 14.6 Diagnosis
7 Female   R, N 5.8 Diagnosis
8 Female   R, N, M 13.8 Diagnosis
9 Male +  R, N, M 18.7 After ASCT
10 Female   R, N, M 5.2 Diagnosis
Note: ASCT = autologous stem cell transplantation; M = monocytes; N = neutrophils; PNH = paroxysmal nocturnal hemoglobinuria; R = red blood cells.
aSex represents sex of the patient.bThe ``+'' and ``'' signs for the columns CD55 and CD59 reflect the presence (+) or absence () of the surface marker.cCell lines represent the types of cells found to be deficient in CD55 and/or
CD59.dClone size represents the largest percentage of PNH cells reported in any of the consecutive measurements in each patient.
eTiming reflects the time of first identification of the clone, with respect to multiple myeloma course.
Table 1. continued
All patients at
diagnosis (n = 31)
Patients with PNH clones
at diagnosis (n = 9)
Patients without PNH clones
at diagnosis (n = 22)
p
Induction chemotherapy
Vincristin–Adriamycin–dexamethasone 1 1 0
Bortezomib–adriamycin–dexamethasone 8 3 5
Bortezomib–dexamethasone 21 5 16
Lenalidomide 1 0 1
Response to induction chemotherapy .801
sCR/CR 11 4 7
VGPR/PR 16 4 12
No response/death 4 1 3
Patients submitted to ASCT 24 7 17
Response to ASCT .284
sCR/CR 16 3 13
VGPR/PR 6 3 3
No response/death 2 1 1
Progression-free survival (mo) Not reached 26 Not reached .118
Overall survival (mo) Not reached Not reached Not reached .846
Bold values indicate significant correlations.
Note: ASCT = autologous stem cell transplantation; ESR = erythrocyte sedimentation rate; Hb = hemoglobin; Ig = immunoglobulin; ISS = International Staging System; LDH = serum lactate dehydrogenase; PNH = paroxysmal
nocturnal hemoglobinuria; sCR/CR = (stringent) complete response; VGPR/PR = (very good) partial response; WBC = white blood cell.
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Figure 2. Graph demonstrating clone-size variation in relation to ASCT for the 10 patients with PNH cells. Case numbers correspond to Table 3.
Note: ASCT = autologous stem cell transplantation; mo = months; PNH = paroxysmal nocturnal hemoglobinuria.
Figure 3. Kaplan–Meier curves for progression-free survival and overall survival between the two groups of patients (with and without paroxysmal
nocturnal hemoglobinuria clone).
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This study was designed to investigate prospectively
the presence and the putative clinical signiﬁcance of
PNH clones in MM patients undergoing ASCT.
The PNH clones may be identiﬁed by FC in
approximately one of three patients (10/31) with
MM. This conﬁrms the previous reports. However,
these reports were based on demonstration of
CD55/CD59-deﬁcient populations in erythrocytes
only; an obsolete method was applied in the previous
studies.14,15,18 In this study, we applied the current
guidelines for detecting PNH clones, wherein we per-
formed ﬂow cytometric analysis on neutrophils and
monocytes as well, requiring the presence of
CD55/CD59-deﬁcient populations in at least two dif-
ferent cell lines before accepting a ‘‘PNH positive’’
result.
Compared with the previous reports in MM, there
are certain differences in the frequency of PNH cell
phenotypes described. Notably, the CD55/CD59
phenotype was predominant in our patients in con-
trast to previous studies. Furthermore, neither of
these studies reported isolated CD59-deﬁcient popu-
lations. The differences may reﬂect effects of different
methodologies adopted. Of note, our results were
unbiased because our sample consisted of consecutive
unselected patients. The correlation between female
sex and deﬁciency of both CD55 and CD59 is not
reported in the aforementioned studies, probably
because they both reported very few patients with
the CD55/CD59 phenotype. This ﬁnding is not
easy to explain. Observations showing that PNH is
affecting slightly more females in Europe19,20 may
partly explain our results.
None of the previous studies reported PNH clone
sizes; therefore, for the ﬁrst time, we demonstrate that
clones may reach signiﬁcant sizes, up to a mean of
10.8% CD55 and/or CD59 cells.
Furthermore, we tested for PNH several times
throughout the myeloma course, whereas previous
results are based on a single test. This allowed us to
observe the new appearance of PNH cells after
ASCT, a ﬁnding not previously reported. The emer-
gence of PNH clones has been reported in AA fol-
lowing treatment with antithymocyte globulin and
cyclosporine.21 Taking into account that ASCT is
an analogous event in terms of immunosuppression,
our ﬁnding is not surprising and points to the sus-
pected immunological mechanisms behind PNH
clone expansion. We demonstrated the disappearanceHematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015of PNH cells in subsequent testing, which agrees with
the ﬁndings of Scheinberg et al.,21 where many
patients demonstrated short-lived clones (identiﬁed
only once or twice) with sizes smaller than 50%,
appearing 3–6 months after treatment.
Because PNH clones found in healthy individuals
have a mean size of 0.002%, our clones cannot be con-
sidered coincidental.10 Therefore, there must be a
mechanism that allows such clones to expand in the
context of MM, as in AA and MDSs. Regarding
AA, PNH clones may be identiﬁed in approximately
40–50% of patients by conventional FC or in up to
70% of patients by higher sensitivity (FLAER) assays;
the sizes are usually less than 20%; however, they may
occasionally be larger.22–25 Regarding MDSs, a recent
study reported detection of PNH cells in approxi-
mately 6.6% of patients with clones having a mean
size of less than 1%.26 Previous studies indicated
PNH clones in 10–20% of patients with
MDSs.27,28 Clone sizes showed big discrepancies in
the following studies: Iwanaga et al.27 reported clones
with a mean size of 38.5%; Wang et al.28 reported
sizes up to 2.41%, with only 3.3% of the patients
demonstrating sizes larger than 1%. Compared with
these results, our ﬁndings show that PNH clones
associated with MM may expand to sizes similar to
those reported in AA, whereas the percentage of
patients harboring these clones should lie somewhere
in between that reported for AA and MDSs.
The most important ﬁnding of our study is the
possible clinical signiﬁcance of such clones. Clones
with sizes less than 20% usually do not have any clin-
ical manifestations other than subclinical hemolysis,
evidenced by raised serum LDH and reticulocyte
counts.17 Our ﬁndings agree with this, as none of
our patients demonstrated clinically signiﬁcant hemol-
ysis, despite observing signiﬁcant correlations with
both LDH and reticulocyte counts and the presence
of the clones. Notwithstanding this low-grade sub-
clinical hemolysis, a correlation with the degree of
anemia was not observed but this may be because
patients with PNH clones had signiﬁcantly lower
bone marrow plasmacytic inﬁltration. This latter ﬁnd-
ing is not easy to explain, especially as no correlation
was found between the presence of clones and mye-
loma staging. It may point to altered plasma cell inter-
actions with the marrow microenvironment in the
presence of PNH cells.
No other symptoms attributed to the PNH clones
were observed, including thrombosis, esophageal
spasm, or atypical abdominal pain. Furthermore,157
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blood counts at diagnosis did not differ signiﬁcantly
between patients with and without clones.
Therefore, we conclude that PNH clones did not
worsen the expected bone marrow failure caused by
plasmacytic inﬁltration. The fact that hematological
toxicity following induction chemotherapy and
ASCT as well as stem cell harvest did not correlate
with the presence of clones implies that presence of
the clones does not essentially inﬂuence bone marrow
function.
By demonstrating a possible link between PNH
clones and advanced (Scale 3) bone disease, we are
conﬁrming the ﬁndings of a previous report, in which
increased bone resorption was observed in MM
patients with PNH clones.15 Despite this ﬁnding,
no correlation was found between the presence of
clones and Durie–Salmon disease stage, where Scale
3 bone disease was enough to characterize MM as
Stage III.29
Response to either induction chemotherapy or
ASCT was not correlated with the presence of the
clones. Recurrence of clones was not observed in rela-
tion with MM relapse. Furthermore, OS was similar
for the two groups of patients, implying that the pres-
ence of clones is not detrimental. Although acorrelation of clones with PFS did not reach statistical
signiﬁcance, the corresponding Kaplan–Meier curve
points to the possible existence of a correlation if
the sample becomes larger. Such an observation could
have important clinical implications, and therefore, we
believe that further studies should be conducted in
this ﬁeld.
In this study, we did not investigate the biological
mechanisms behind PNH clone expansion in MM. A
hypothesis to explain our ﬁndings would probably
point to the immune dysfunction in MM, allowing
for clone expansion. Treatment of MM restores
immune function; it may also directly affect PNH
cells, being more susceptible to lysis, leading to
decreasing clone sizes. Emergence of new clones fol-
lowing ASCT highlights the role of immune deﬁ-
ciency and the alteration of T-cell repertoire, as
immune recovery eventually leads to the disappear-
ance of clones a few months after ASCT.CONFLICTS OF INTEREST
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